Giacomo Chiesi

Sentien’s mission is to harness the power of cell therapy with innovative drug delivery systems to treat a wide range of acute inflammatory diseases. Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.

Palladio Biosciences, Inc., is a private biotech company founded in 2015 to develop medicines for orphan drug diseases of the kidney. Our first product, lixivaptan, is being re-positioned for the treatment of polycystic kidney disease (PKD). PKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. It is the 4th leading cause of kidney failure and carries significant financial and emotional burden, affecting entire families. There is no cure for PKD. We are developing lixivaptan as a safe and effective agent to be used chronically to prevent the progression of PKD.

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The companys approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org

Sentien’s mission is to harness the power of cell therapy with innovative drug delivery systems to treat a wide range of acute inflammatory diseases. Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.

Palladio Biosciences, Inc., is a private biotech company founded in 2015 to develop medicines for orphan drug diseases of the kidney. Our first product, lixivaptan, is being re-positioned for the treatment of polycystic kidney disease (PKD). PKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. It is the 4th leading cause of kidney failure and carries significant financial and emotional burden, affecting entire families. There is no cure for PKD. We are developing lixivaptan as a safe and effective agent to be used chronically to prevent the progression of PKD.

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The companys approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.